Title of Invention	PROCESS FOR TRANSITION METAL-CATALYZED ASYMMETRIC HYDROGENATION OF ACRYLIC ACID DERIVATIVES, AND A NOVEL CATALYST SYSTEM FOR ASYMMETRIC TRANSITION METAL CATALYSIS
Abstract	A process for transition metal-catalyzed, asymmetric hydrogenation of acrylic acid derivatives of the formula (I) in which R1 is H or an optionally substituted alkyl, aryl or heteroaryl radical, R2 is an optionally substituted alkyl, aryl or heteroaryl radical, and R3 is H or a C<SUB>K/SUB>-C<SUB>6</SUB>-alkyl radical, which comprises hydrogenatmg compounds of the formula (I), optionally in a solvent, in the presence of one or more hydrogen donors, using a catalyst system which comprises a transition metal from the group of ruthenium, rhodium and indium and a combination of a chiral phosphorus ligand of the formula (II) in which Cn, together with the two oxygen atoms and the phosphorus atom, forms an optionally substituted ring having from 2 to 6 carbon atoms and R4 is an optionally substituted alkyl, aryl, alkoxy or aryloxy radical or NR5R6 where R5 and R6 may each independently be H or an optionally substituted alkyl, aryl, aralkyl or alkaryl radical, or, together with the nitrogen atom, may form a ring, and an achiral phosphine ligand of the formula (III) in which R is an optionally substituted alkyl or aryl radical, to the corresponding compounds of the formula (IV) in which R1, R2 and R3 are each as defined above, and also a novel catalyst system for asymmetric transition metal catalysis.

Title of Invention

PROCESS FOR TRANSITION METAL-CATALYZED ASYMMETRIC HYDROGENATION OF ACRYLIC ACID DERIVATIVES, AND A NOVEL CATALYST SYSTEM FOR ASYMMETRIC TRANSITION METAL CATALYSIS

Abstract

A process for transition metal-catalyzed, asymmetric hydrogenation of acrylic acid derivatives of the formula (I) in which R1 is H or an optionally substituted alkyl, aryl or heteroaryl radical, R2 is an optionally substituted alkyl, aryl or heteroaryl radical, and R3 is H or a C<SUB>K/SUB>-C<SUB>6</SUB>-alkyl radical, which comprises hydrogenatmg compounds of the formula (I), optionally in a solvent, in the presence of one or more hydrogen donors, using a catalyst system which comprises a transition metal from the group of ruthenium, rhodium and indium and a combination of a chiral phosphorus ligand of the formula (II) in which Cn, together with the two oxygen atoms and the phosphorus atom, forms an optionally substituted ring having from 2 to 6 carbon atoms and R4 is an optionally substituted alkyl, aryl, alkoxy or aryloxy radical or NR5R6 where R5 and R6 may each independently be H or an optionally substituted alkyl, aryl, aralkyl or alkaryl radical, or, together with the nitrogen atom, may form a ring, and an achiral phosphine ligand of the formula (III) in which R is an optionally substituted alkyl or aryl radical, to the corresponding compounds of the formula (IV) in which R1, R2 and R3 are each as defined above, and also a novel catalyst system for asymmetric transition metal catalysis.

Full Text	Process for transition metal-catalyzed asymmetric hydrogenation of acrylic ac1d derivatives, and a novel catalyst system for asymmetric transition metal catalysis The present invention relates to a process for transition metal-catalyzed asymmetric hydrogenation of acrylic ac1d derivatives, for instance alpha-substituted c1nnamic ac1d derivatives, to the corresponding chiral ac1ds or esters, and also a novel catalyst system with a spec1fic ligand system consisting of a chiral phosphorus ligand and an achiral phosphine ligand for asymmetric catalysis. Acrylic ac1d derivatives, for instance alpha-substituted c1nnamic ac1d derivatives, constitute valuable intermediates for the preparation of Pharmaceuticals, for instance for delta-amino-gamma-hydroxy-omega-arylalkanecarboxamides, which have renin-inhibiting properties and can be used as an ant ihyper tensive in pharmaceutical preparations. Catalysts, and also processes for transition metal-catalyzed asymmetric hydrogenations of unsaturated compounds, have already been described in the literature. For example, WO 02/0250-0 states that the asymmetric hydrogenation of alpha,beta-unsaturated carboxylic ac1ds with homogeneous, asymmetric hydrogenation catalysts is known per se and that spec1fically ruthenium and rhodium catalysts are very effective therefor. The ligands used are chiral di-tertiary diphoaphines. With these systems, it is possible according to WO 02/02500 to attain optical yields of up to 80% ee. As an improvement to these catalysts, WO 02/02500 proposes the use of a bidentate ligand with a ferrocenyl basic structure. Adv. Synth. Catal. 2003, 345, p. 160-164 discloses further diphoBphine ligands based on a ferrocenyl-aryl basic structure, known as the walphos ligand family, which are used in the rhodium- or ruthenium-catalyzed asymmetric hydrogenation of olefins and ketones. The walphos iigands are used in combination with a ruthenium or a rhodium source, for instance Ru( methyl allyl)2COD, [ (NBD) 2Rh] BF4 or [ (COD) 2Rh] BF4, for example for the hydrogenation of c1nnamic ac1d derivatives, in which optical purities of up to 95% ee are achieved. A disadvantage in this process is in particular the high costs of the walphos ligand, since the synthesis of the ligand is distinctly more complicated. WO 02/04466 discloses further catalysts which have a monodentate ligand. However, it has been found that the monophos catalyst systems described therein are less active for c1nnamic ac1d derivatives in particular, as a result of which longer hydrogenation times are required, and lead to poorer enantiomeric excesses. WO 2004/03520B describes mixtures of monophosphorus compounds as ligand systems for asymmetric transition metal catalysis. It is known from Example 8 of the application that a mixture of chiral phosphonite or phosphite ligands and an achiral monophosphorus ligand leads to distinctly poorer results with regard to optical purity than when a mixture of chiral monophosphorus compounds is used. Since there is still a great need for improved processes with improved catalyst systems in the field of asymmetric hydrogenation of acrylic ac1d derivatives, it is an object of the present invention to find a process for transition metal-catalyzed asymmetric hydrogenation of acrylic ac1d derivatives, and also a novel catalyst system which enables, in a simple, inexpensive manner, the preparation of the desired compoundB in optical purities, higher compared to the prior art, of up to 100% ee, and in higher yields of up to 100% of theory. The present invention accordingly provides a process for transition ,metal-catalyzed, asymmetric hydrogenation of acrylic ac1d derivatives of the formula (I) in which Rl is H or an optionally substituted -alkyl, -aryi or -heteroaryl radical, R2 is an optionally substituted.lkyl, C5-C2o-aryl or -heteroaryl radical, and R3 is H or. a d-C6-alkyl radical, which comprises hydrogenating compounds of the formula (I), (Formula Removed) optionally in a solvent, in the presence of one or more H donors, using a catalyst system which comprises a transition metal from the group of ruthenium, rhodium and iridium and a combination of a chiral phosphorus ligand of the formula (II) (Formula Removed) in which Cn, together with the two oxygen atoms and the phosphorus atom, forms an optionally substituted ring having from 2 to 6 carbon atoms and R4 is an optionally substituted alkyl, aryl, alkoxy or aryloxy radical or NR5R6 where R5 and R6 may each independently be H or an optionally substituted alkyl, aryl, aralkyl or alkaryl radical, or, together with the nitrogen atom, may form a ring, and an achiral phosphine ligand of the formula (III) (Formula Removed) in which R is an optionally substituted alkyl or aryl radical, to the corresponding compounds of the formula (IV) in which Rl, R2 and R3 are each as defined above. The substrates used are acrylic ac1d derivatives of the formula (I) in which Rl is H or an optionally substituted C1-C20-alkyl radical or an optionally substituted C5-C20-aryl or C5-C20-heteroaryl radical, and R2 is an optionally substituted C1-C20-alkyl radical or an optionally substituted C5-C20-aryl or C5-C20-heteroaryl radical. Alkyl radicals should be understood to mean linear, branched or cyclic alkyl radicals having from 1 to 20 carbon atoms, where the alkyl chain may optionally contain one or more double or triple bonds or may be interrupted by one or more heteroatoms from the group of N, 0 and S. Examples of alkyl radicals are methyl, ethyl, n-propyl, i-propyl, propenyl, n-butyl, t-butyl, cyclopentyl, butynyl, n-hexyl, cyclohexyl, i-octyl, undecyl, neoheptyl, pentadecyl, tetrahydropyrrolyl, tetrahydrofuranyl, dimethyl sulfide, etc. Preference is given to linear, branched or cyclic alkyl radicals having from 1 to 12 carbon atoms, where the alkyl chain may optionally have a double or triple bond and may optionally contain a heteroatom. Aryl and heteroaryl radicals are aromatic radicals having from 5 to 20 carbon atoms, for instance cyclopenradienyl, phenyl, biphenylyl , indenyl , naphthyl, pyrrolyl, f uranyl , indolyl , pyrridinyl, etc. Preference is given to phenyl or naphthyl . he radicals may be mono- or polysubstituted by suitable substituents . Suitable substituents are, for example, C1-C20-alkoxy groups, preferably C1-C12-alkoxy groups, C1-C20-alkyl groups, preferably C1-C6 alkyl, C6-C20-aryl groups, preferably phenyl, trif luoro-C1 -C6-alkyl, preferably trifluoromethyl, poly-C1-C20-alkoxy groups, halogen, for instance F, Cl , Br or I, hydroxyl, amines, nitro, nitrile, carboxylic ac1ds, carboxylic esters or carboxamides , etc . Particularly preferred substituents are Ca-C6-alkoxy groups, C1-C6-alkyl groups, trifluoromethyl, poly-CS-Cs-alkoxy groups, F, Cl or Br. R3 is either E or a C1-Ce-alkyI radical. Particularly preferred substrates are those compounds of the formula (I) in which R2 is phenyl or a C1-Cg-alkyl group, and Rl is an optionally mono- or polysubstituted phenyl radical, and R3 is H. The process according to the invention for transition metal -catalyzed asymmetric hydrogenation of acrylic ac1d derivatives of the formula (I) proceeds in the presence of one or more hydrogen donors. In this context, hydrogen donors should be understood to mean compounds which are capable of transferring H to the substrate, for instance H2, aliphatic or aromatic GI-C1O alcohols, for instance i-propanol or cyclohexanol , unsaturated hydrocarbons having 5-10 carbon atoms, for instance 1, 4 -dihydrobenzene or hydroquinone , or a mixture of formic ac1d and triethylamine, etc. (see WO 02/04466) . In some cases, for example in the case of use of an alcohol or of a hydrocarbon, the hydrogen donor can also serve as a solvent, so that no additional solvent has to be used. Preference is given to using H2 as the hydrogen donor. The hydrogen pressure in the process according to the invention is from 1 to 200 bar, preferably from 10 to 150 bar and more preferably from 15 to 100 bar. The reaction temperature is between -20 °C and +120°C, preferably from 0 to 80°C and more preferably from 20 to 65°C. The asymmetric hydrogenation is preferably effected with exclusion of oxygen. The process according to the invention is optionally carried out in a solvent. Suitable solvents are preferably organic solvents, for example alcohols, esters, amides, ethers, ketones, aromatic hydrocarbons and halogenated hydrocarbons. Particular preference is given to using protic solvents. Examples of preferred solvents are ethyl acetate, methanol, i-propanol, acetone, tetrahydrofuran, dichloromethane, toluene or dibromoethane. If desired, it is also possible to use a mixture of one or more of the solvents listed above with water. The volume ratio of solvents to water is then preferably from 2:1 to 8:1, more preferably from 3:1 to 6:1. Preference is given to a mixture of one or more protic solvents with water, as a result of which a distinct increase in the enantiomeric purity can be achieved. The solvent used in the process according to the invention is more preferably a mixture of i-propanol and water. The catalyst used in accordance with the invention is a catalyst system which comprises a transition metal from the group of ruthenium, rhodium and iridium, and a combination of a chiral phosphorus ligand of the formula (II) and an achiral phosphine ligand of the formula (III). The transition metal used is preferably ruthenium or rhodium, more preferably rhodium. Chiral ligands of the formula (II) are known and are described, for example, in WO 02/04466 or WO 2004/035208. In the formula (II), the alkyl, aryl, alkoxy,, aryloxy, aralkyl or alkaryl groups preferably have 1-20 carbon atoms and may optionally be substituted by one or more substituents from the group of hydroxyl, alkyl, alkoxy, phenyl, nitrile, carboxylic ester or halogen. R4 in the formula (II) is more preferably an optionally substituted, linear, branched or cyclic C1-CB-alkyl radical, an optionally substituted phenyl radical, an optionally substituted C1-CB-alkoxy radical, an optionally substituted phenyloxy radical or an NR5R6 group in which R5 and R6 are preferably each independently an optionally phenyl-substituted alkyl group having 1-6 carbon atoms, more preferably having 1-3 carbon atoms, or, together with the nitrogen atom, form a ring which may optionally also contain a heteroatom, for instance 0, N or S, for instance a morpholine ring, piperxdine ring, pyrrolidine ring, etc. More preferably, R5 and R6 with the nitrogen atom form a 5-Tnembered or 6-membered ring which may optionally also contain a heteroatom. Cn is preferably a chiral, substituted C4 chain (chain with 4 optionally substituted carbon atoms) with predominantly one configuration, for example with an enantiomeric excess greater than 95% ee, preferably above 99% ee. together with the two oxygen atoms and the phosphorus atom more preferably forms a 7-membered ring having 4 carbon atoms, in which case two carbon atoms in each case are part of an optionally substituted aryl group. The aryl group is more preferably an optionally substituted phenyl or naphthyl group. The substituents are preferably attached in the o positions. Examples of preferred chiral ligands of the formula (II) are compounds of the formula (Ila) and (lib) where the naphthyl groups are optionally mono- or polysubstituted by halogen, for instance chlorine or bromine, alkyl, preferably C1-C6-alkyl, or alkoxy, preferably C1-Cs-alkoxy, aryl, preferably phenyl, aryloxy, preferably phenyloxy, R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-Ce-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, and R5 and R6 are each independently an optionally phenyl-substituted alkyl group having 1-6 carbon atoms, more preferably having 1-3 carbon atoms, or, together with the nitrogen atom, form a ring. Further preferred chiral ligands of the formula (II) are compounds of the formula (lie) and (lid) (Figure Removed) where the phenyl groups are optionally mono- or polysubstituted by halogen, for instance chlorine or bromine; alkyl, preferably - alkyl, or alkoxy, preferably -alkoxy, aryl , preferably phenyl, aryloxy, preferably phenyl oxy, R4 is an optionally substituted -alkyl radical, an optionally substituted phenyl radical, an optionally phenyl -substituted - alkoxy radical or an optionally -alkyl- substituted phenyl oxy radical, and R5 and R6 are each independently an optionally phenyl -substituted alkyl group having 1-6 carbon atoms, more preferably having 1-3 carbon atoms, or, together with the nitrogen atom, form a ring. Particularly preferred chiral ligands of the formula (II) are compounds of the formula (lie) and (Ilf) in which R4 is an optionally substituted -alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-Ce-alkoxy radical or an optionally Cx-Ce-alkyl-substituted phenyloxy radical, R5 and R6 are each independently a Ca-C6-alkyl group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 a linear or branched C1-C6-alkyi radical, an optionally substituted phenyl radical, an optionally phenyl -substituted in which R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C^-alkoxy radical or an optionally C1-Cg-alkyl-substituted phenyioxy radical, R5 and R6 are each independently a d-Ce-alkyl group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 and R8 are each a linear or branched C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted d-C6-alkoxy radical, or an optionally C1-C6-alkyl-substituted phenyloxy radical. The chiral ligands are used with an enantiomeric purity of at least 50% ee, preferably of at least 90% ee and more preferably of above 99% ee. As a second ligand, the catalyst system used in accordance with the invention comprises an achiral phosphine ligand of the formula (III) P(R)3 in which R is an optionally substituted alkyl or aryl radical. R is preferably a linear, branched, or cyclic alkyl radical having from 2 to 10 carbon atoms, more preferably having from 4 to 6 carbon atoms, or a phenyl radical optionally mono- or polysubstituted by halogen or C-.-Cr-alkyl. Particularly preferred radicals are phenyl, o-tolyl, m-tolyl, p-tolyl, xylyl, m-chlorophenyl, p-chlorophenyl, o-methoxyphenyl, p-methoxyphenyl, m-methoxyphenyl, mesityl, cyclohexyl, n-butyl and t-butyl. The ratio of chiral ligand of the formula (II) to achiral ligand of the formula (III) in the process according to the invention is from 10:1 to 1:5, preferably from 5:1 to 1:2, more preferably from 2.5:1 to 1.2:1. The inventive catalyst system can be prepared analogously to WO 02/04466. Preference is given to reacting the chiral ligand and the achiral ligand with a catalyst precursor comprising the transition metal. Examples of suitable catalyst precursors are: (COD = 1, 5-cyclooctadiene, NBD = norbornadiene) [Rh(COD)2Cl]2, [Rh(COD)2]BF4, [Rh (NBD) 2] BF4, Ru(OAc)3, Ru (methyialiyl) 2COD, [Ru (cymene) C12] 2/ etc. The molar ratio of transition metal catalyst:chiral ligand is from 1:0.5 to 1:5, preferably from 1:1 to 1:2. The molar ratio of reactant:transition metal catalyst is from 100:1 to 1 000 OOO-.l, preferably from 1000:1 to 10 000:1. In the process according to the invention, for example, the substrate of the formula (I) , the ligands of the formulae (II) and (III) , and the precursor which comprises the transition metal are dissolved in the solvent in a suitable apparatus, for instance in an autoclave. Then, the apparatus is preferably purged with inert gas, for example with N2/ if the exclusion of oxygen is desired. Then, rhe mixture is heated to the desired reaction temperature. However, preferably only -he substrate is dissolved first in the solvent, then the apparatus is purged, preferably with inert gas. After heating to the appropriate reaction temperature, a suspension of the ligands of the formula (II) and (III) in degassed solvent and also the precursor which comprises the transition metal are then charged to the substrate solution. Afterward, the hydrogen donor is added at the appropriate reaction temperature. Preference is given to injecting H2 to the desired pressure. After the reaction has ended and the reaction solution has optionally been cooled, the desired end product is isolated by customary methods depending on the state of matter. It is also possible first to prepare the catalyst complex, for example by reacting the ligands (II) and (III) with a precursor in a degassed solvent at room temperature, by stirring the reaction mixture for a certain time. Subsequently, the volatile compounds are distilled off to obtain a solid catalyst complex which is then added to the substrate solution. The process according to the invention and in particular the use of the spec1fic catalyst system make it possible to hydrogenate the acrylic ac1d derivatives firstly in a substantially less expensive manner compared to the prior art and secondly in distinctly higher enantioselectively, as a result of which the end products have a distinctly higher optical purity. The present invention further provides a catalyst system for asymmetric transition metal catalysis, which comprises a transition metal from group VIII, IX or X and a combination of a chiral phosphorus ligand of the formula (Ha) , (lib) , (lie) or (lid) and an achiral phosphine ligand of the formula (III) in which R is an optionally substituted alkyl or aryl The inventive catalyst system is suitable for asymmetric transition metal catalysis, in particular for transition metal-catalyzed asymmetric hydrogenation of unsarurated compounds. The ratio of chiral ligand of the formulae (Ha) - (lid) to achiral ligand of the formula (III) may in this case be from 10:1 to 1:5. The ratio is preferably from 5:1 to 1:2, more preferably from 2.5:1 to 1.2:1. Suitable transition metals are elements of groups VIII, IX or X; preference is given to using ruthenium, rhodium or iridium. The invention further provides for the use of the inventive catalyst system for the transition metal-catalyzed asymmetric hydrogenation of unsaturated compounds. Example 1: Preparation of (R] -5-methoxy-3- (3-methorypropoxy)-a-(1-methylethyl)phenylpropanoic ac1d In a 450 mi autoclave, 50 g (178.35 mmol) of E-2-[[4-meuhoxy-S-(3-methoxypropoxy)phenyl]methylene]-3-methylbutanoic ac1d, IOC mg (0.234 mmol) of ligand of the formula (lie) (%ee > 95%) (2,6-dimethyl-3,5-dioxa-4-phosphacyclohepta[2,1-a;3,4-a' ]dinaphthalen-4-yDpiperidine, 47.6 mg (0.1172 mmol) of Rh(COD)2BF4 and 30.8 mg (0.117 mraol) of triphenylphosphine were suspended in 160 ml of isopropanol (IPA) :H20 = 4:1. The autoclave was purged 5x with N2 and heated to 55°C. Afterward, it was purged 3x with H2 and subsequently pressurized to 80 bar of H2 without stirring. At 80 bar/55°C and 100 rptr. of the stirrer, the mixture was then hydrogenated overnight. After 18 h, the autoclave was cooled and the desired product was isolated. Yield: 50,35 g (96.6% of theory) Optical purity: 95.3% ee Examples 2-8: Analogously to Example 1, alpha-methyl c1nnamic ac1d was hydrogenat ed. The reaction parameters were selected as follows: 1 mmol of substrate, reaction temperature 30CC; 25 bar of K2; 4 ml of solvent IPA:H20 = 4:1, reaction time 16 h; 0.01 mmol of Rh(COD) 2BF4, 0.02 mmol of chiral ligand as in Example 1, 0.01 mmol of achiral ligand P(R)3; see Table 1 for R. were hydrogenated. The particular definition of the Rl and R2 radicals is shown in Table 2. The reaction parameters were selected as follows: 1 mmol of substrate, reaction temperature 30°C; 25 bar of H2; 4 ml of solvent IPA:H20 = 4:1, reaction time 16 h; 0.01 mmol of Rh(COD)2BF4, 0.02 mmol of chiral ligand as in Example 1 except that the ring in some cases contains an oxygen atom (see Table 2), 0.01 mmol of achiral ligand P(R)3; see Table 2 for R.Analogously to Examples 2-8, alpha-methylc1nnamic ac1d was hydrogenated. For comparison, hydrogenation was effected in each case once with use of an inventive ligand system consisting of the combination of chiral ligand and. achiral ligand PPh3 and once only with use of a chiral ligand (without achiral ligand). The reaction parameters were selected as follows: 1 rnmol of substrate, reaction temperature 60°C; 25 bar of H2; 4 ml of solvent IPA, reaction time 5 h; 0.01 mmol of Rh(COD)aBF4, 0.02 mmol of chiral ligand of the following formula, and in some cases 0.01 mmol of(Table Removed) What is claimed is: I. A process for transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives of the formula (I) II. (Formula Removed) In which Rl is E or an optionally substituted C1-C20-alkyl, C5-C2o-aryi or C5-C20-heteroaryl radical, R2 is an optionally substituted C1-C20-alkyl, C5-C20)-aryl or C5-C20-heteroaryl radical, and R3 is H or :a C1-C6-alkyl radical, which comprises hydrogenating compounds of the formula (I) , optionally in a solvent, in the presence of one or more hydrogen donors, using a catalyst system which comprises a transition metal from the group of ruthenium, rhodium and iridium and a combination of a chiral phosphorus ligand of the formula (II) (Formula Removed) in which Cn, together with the two oxygen atoms and the phosphorus atom, forms an optionally substituted ring having from 2 to 6 carbon atoms and R4 is an optionally substituted alkyl, aryl, alkoxy or aryloxy radical or NR5R6 where R5 and R6 may each independently be H or an optionally substituted alkyl, aryl, aralkyl or alkaryl radical, or, together with the nitrogen atom, may form a ring, and an achiral phosphine ligand of the formula (III) in which R is an optionally substituted alkyl or aryl radical, to the corresponding compounds of the formula (IV) (Figure Removed) in which Rl, R2 and R3 are each as defined above. 2. The process as claimed in claim 1, wherein suitable hydrogen donors act as solvents or the solvents used are alcohols, esters, amides, ethers, ketones, aromatic hydrocarbons and halogenated hydrocarbons, optionally in combination with water. 3. The process as claimed in claim 2, wherein the solvents are used in combination with water, the volume ratio of solvent to water being from 2:1 to 8:1. 4. The process as claimed in claim 3, wherein the solvent used is a mixture of 2-propanol and water in a volume ratio of from 3:1 to 6:1. 5. The process as claimed in one of claims 1 to 4, wherein the hydrogen donor used is H2. 6. The process as claimed in one of claims 1 to 5, wherein the reaction temperature is between -20DC and +120°C. 7. The process as claimed in one of claims 1 to 6, wherein the chiral ligand is used with an enantiomeric purity of at least 90% ee. 8. The process as claimed in one of claims 1 to 7, wherein the transition metal used is ruthenium or rhodium. 9. The process as claimed, in one of claims 1 to 8, wherein chiral ligands of the formula (II) are used in which R4 is an optionally substituted, linear, branched of cycli C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally substituted C1-C6-alkoxy radical, an optionally substituted phenyloxy radical or an NR5R6 group where R5 and R6 are each independently an optionally phenyl-substituted alkyl group having 1-6 carbon atoms or, together with the nitrogen atom, form a ring which may optionally also contain a heteroatoin. 10. The process as claimed in one of claims 1 to 9, wherein chiral ligands of the formula (IIa), (Figure Removed) ere the naphthyi and the phenyl groups may optionally be mono- or polysubstituted by halogen, alkyl, alkoxy, aryl or aryloxy, R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C6-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, and R5 and R6 are each independently a phenyl-substituted alkyl group having 1-6 carbon atoms or, together with the nitrogen atom, form a ring are used. 11. The process as claimed in one of claims 1-10, wherein chiral ligands of the formula (lie), (IIf), (IIg) or (IIh) (Figure Removed) in which R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C6-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, R5 and R6 are each independently a C1-C6-alky! group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 and R8 are each a linear or branched C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted d-Ce-alkoxy radical, or an optionally C1-C6-alkyl-substituted phenyloxy radical are used. 12. The process as claimed in one of claims 1-11, wherein achiral ligands of the formula (III) are used in which R is a linear, branched or cyclic alkyl radical having from 2 to 10 carbon atoms or a phenyl radical optionally mono- or polysubstituted by halogen or C1-C6-alkyl. 13. The process as claimed in one of claims 1-12, wherein the ratio of chiral ligand of the formula (II) to achiral ligand of the formula (III) is from 10:1 to 1:5. The process as claimed in one of claims 1-13, wherein the molar ratio of transition metal catalyst to chiral ligand of the formula (II) is from 1:0.5 to 1:5. 15. The process as claimed in one of claims 1-14, wherein the transition metal is used in the form of a catalyst precursor. 16. The process as claimed in one of claims 1-15, wherein the substrate of the formula (I) , the ligands of the formulae (II} and (III) , and the precursor which comprises the transition metal are first dissolved in the solvent in a suitable apparatus, then the apparatus is optionally purged with inert gas and then heated to the desired reaction temperature, or only the substrate of the formula (I) is first dissolved in the solvent, then the apparatus is optionally purged with inert gas, and only after heating to the appropriate reaction temperature is a suspension of the ligands of the formula (II) and (III) in degassed solvent and also the precursor which comprises the transition metal charged to the substrate solution, and then, in both cases, the hydrogen donor is added at the appropriate reaction temperature. 17. A catalyst system for asymmetric transition metal catalysis, which comprises a transition metal from group VIII, IX or X and a combination of a chiral phosphorus ligand of the formula (Ha) , (lib) , (IIe) or (IId) (Figure Removed) where the naphthyl and the phenyl groups may optionally be mono- or polysubstituted by halogen, alkyi, alkoxy, aryl or aryloxy, R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C6-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, and R5 and R6 are each independently a phenyl-substituted alkyl group having 1-6 carbon atoms or, together with the nitrogen atom, form a ring, and an achiral phosphine ligand of the formula (III) P(R)3 in which R is an optionally substituted alkyl or aryl radical. The catalyst system as claimed in claim 17, wherein the transition metal used is ruthenium, rhodium or iridium. 19. The catalyst system as claimed in claim 17 or 18, wherein the chiral ligand used is a ligand of the formula (He) , (IIf) , (Ilg) or (IIh) (Figure Removed) in which R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical or an optionally phenyl-substituted C1-C6-alkoxy radical, R5 and R6 are each independently a C1-C6-alkyl group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 and RB are each a linear or branched C1-C6-alkyl radical. 20. The catalyst system as claimed in one of claims 17 to 19, wherein the molar ratio of chiral ligand to achiral ligand is from 2.5:1 to 1.2:1. 21. The use of a catalyst system as claimed in one of claims 17 to 20 in transition metal-catalyzed asymmetric hydrogenation of unsaturated compounds. 22. The use as claimed in claim 21, wherein the unsaturated compounds are acrylic acid derivatives of the formula (I) (Formula Removed) in which R1 is H - optionally substituted alkyl, C5-C20{aryl or C5-C20-heteroar%'l .radical, R2 is an 4ptionally substituted C2-C20-aikyl, C5-C20-aryl or -heteroaryl radical, and R3 is H or a C2-C6-alKyl radical.

Full Text

Process for transition metal-catalyzed asymmetric hydrogenation of acrylic ac1d derivatives, and a novel catalyst system for asymmetric transition metal catalysis
The present invention relates to a process for transition metal-catalyzed asymmetric hydrogenation of acrylic ac1d derivatives, for instance alpha-substituted c1nnamic ac1d derivatives, to the corresponding chiral ac1ds or esters, and also a novel catalyst system with a spec1fic ligand system consisting of a chiral phosphorus ligand and an achiral phosphine ligand for asymmetric catalysis.
Acrylic ac1d derivatives, for instance alpha-substituted c1nnamic ac1d derivatives, constitute valuable intermediates for the preparation of Pharmaceuticals, for instance for delta-amino-gamma-hydroxy-omega-arylalkanecarboxamides, which have renin-inhibiting properties and can be used as an ant ihyper tensive in pharmaceutical preparations.
Catalysts, and also processes for transition metal-catalyzed asymmetric hydrogenations of unsaturated compounds, have already been described in the literature.
For example, WO 02/0250-0 states that the asymmetric hydrogenation of alpha,beta-unsaturated carboxylic ac1ds with homogeneous, asymmetric hydrogenation catalysts is known per se and that spec1fically ruthenium and rhodium catalysts are very effective therefor. The ligands used are chiral di-tertiary diphoaphines. With these systems, it is possible according to WO 02/02500 to attain optical yields of up to 80% ee. As an improvement to these catalysts, WO 02/02500 proposes the use of a bidentate ligand with a ferrocenyl basic structure.
Adv. Synth. Catal. 2003, 345, p. 160-164 discloses further diphoBphine ligands based on a ferrocenyl-aryl basic structure, known as the walphos ligand family, which are used in the rhodium- or ruthenium-catalyzed asymmetric hydrogenation of olefins and ketones. The walphos iigands are used in combination with a ruthenium or a rhodium source, for instance Ru( methyl allyl)2COD, [ (NBD) 2Rh] BF4 or [ (COD) 2Rh] BF4, for example for the hydrogenation of c1nnamic ac1d derivatives, in which optical purities of up to 95% ee are achieved.
A disadvantage in this process is in particular the high costs of the walphos ligand, since the synthesis of the ligand is distinctly more complicated. WO 02/04466 discloses further catalysts which have a monodentate ligand. However, it has been found that the monophos catalyst systems described therein are less active for c1nnamic ac1d derivatives in particular, as a result of which longer hydrogenation times are required, and lead to poorer enantiomeric excesses. WO 2004/03520B describes mixtures of monophosphorus compounds as ligand systems for asymmetric transition metal catalysis. It is known from Example 8 of the application that a mixture of chiral phosphonite or phosphite ligands and an achiral monophosphorus ligand leads to distinctly poorer results with regard to optical purity than when a mixture of chiral monophosphorus compounds is used.
Since there is still a great need for improved processes with improved catalyst systems in the field of asymmetric hydrogenation of acrylic ac1d derivatives, it is an object of the present invention to find a process for transition metal-catalyzed asymmetric hydrogenation of acrylic ac1d derivatives, and also a novel catalyst system which enables, in a simple, inexpensive manner, the preparation of the desired compoundB in optical purities, higher compared
to the prior art, of up to 100% ee, and in higher yields of up to 100% of theory.
The present invention accordingly provides a process for transition ,metal-catalyzed, asymmetric hydrogenation of acrylic ac1d derivatives of the formula (I)
in which Rl is H or an optionally substituted -alkyl, -aryi or -heteroaryl radical, R2 is an optionally substituted.lkyl, C5-C2o-aryl or -heteroaryl radical, and R3 is H or. a d-C6-alkyl radical, which comprises hydrogenating compounds of the formula (I),
(Formula Removed)
optionally in a solvent, in the presence of one or more H donors, using a catalyst system which comprises a transition metal from the group of ruthenium, rhodium and iridium and a combination of a chiral phosphorus ligand of the formula (II)
(Formula Removed)
in which Cn, together with the two oxygen atoms and the phosphorus atom, forms an optionally substituted ring having from 2 to 6 carbon atoms and R4 is an optionally substituted alkyl, aryl, alkoxy or aryloxy radical or NR5R6 where R5 and R6 may each independently be H or an optionally substituted alkyl, aryl, aralkyl or alkaryl radical, or, together with the nitrogen atom, may form a ring, and an achiral phosphine ligand of the formula (III)
(Formula Removed)
in which R is an optionally substituted alkyl or aryl radical, to the corresponding compounds of the formula (IV)
in which Rl, R2 and R3 are each as defined above.
The substrates used are acrylic ac1d derivatives of the formula (I) in which Rl is H or an optionally substituted C1-C20-alkyl radical or an optionally substituted C5-C20-aryl or C5-C20-heteroaryl radical, and R2 is an optionally substituted C1-C20-alkyl radical or an optionally substituted C5-C20-aryl or C5-C20-heteroaryl radical.
Alkyl radicals should be understood to mean linear, branched or cyclic alkyl radicals having from 1 to 20 carbon atoms, where the alkyl chain may optionally contain one or more double or triple bonds or may be interrupted by one or more heteroatoms from the group of N, 0 and S.
Examples of alkyl radicals are methyl, ethyl, n-propyl, i-propyl, propenyl, n-butyl, t-butyl, cyclopentyl, butynyl, n-hexyl, cyclohexyl, i-octyl, undecyl, neoheptyl, pentadecyl, tetrahydropyrrolyl, tetrahydrofuranyl, dimethyl sulfide, etc. Preference is given to linear, branched or cyclic alkyl radicals having from 1 to 12 carbon atoms, where the alkyl chain may optionally have a double or triple bond and may optionally contain a heteroatom.
Aryl and heteroaryl radicals are aromatic radicals having from 5 to 20 carbon atoms, for instance
cyclopenradienyl, phenyl, biphenylyl , indenyl , naphthyl, pyrrolyl, f uranyl , indolyl , pyrridinyl, etc. Preference is given to phenyl or naphthyl .
he radicals may be mono- or polysubstituted by suitable substituents .
Suitable substituents are, for example, C1-C20-alkoxy groups, preferably C1-C12-alkoxy groups, C1-C20-alkyl groups, preferably C1-C6 alkyl, C6-C20-aryl groups, preferably phenyl, trif luoro-C1 -C6-alkyl, preferably trifluoromethyl, poly-C1-C20-alkoxy groups, halogen, for instance F, Cl , Br or I, hydroxyl, amines, nitro, nitrile, carboxylic ac1ds, carboxylic esters or carboxamides , etc .
Particularly preferred substituents are Ca-C6-alkoxy groups, C1-C6-alkyl groups, trifluoromethyl, poly-CS-Cs-alkoxy groups, F, Cl or Br.
R3 is either E or a C1-Ce-alkyI radical.
Particularly preferred substrates are those compounds of the formula (I) in which R2 is phenyl or a C1-Cg-alkyl group, and Rl is an optionally mono- or polysubstituted phenyl radical, and R3 is H.
The process according to the invention for transition metal -catalyzed asymmetric hydrogenation of acrylic ac1d derivatives of the formula (I) proceeds in the presence of one or more hydrogen donors. In this context, hydrogen donors should be understood to mean compounds which are capable of transferring H to the substrate, for instance H2, aliphatic or aromatic GI-C1O alcohols, for instance i-propanol or cyclohexanol , unsaturated hydrocarbons having 5-10 carbon atoms, for instance 1, 4 -dihydrobenzene or hydroquinone , or a mixture of formic ac1d and triethylamine, etc. (see WO 02/04466) .

In some cases, for example in the case of use of an alcohol or of a hydrocarbon, the hydrogen donor can also serve as a solvent, so that no additional solvent has to be used.
Preference is given to using H2 as the hydrogen donor. The hydrogen pressure in the process according to the invention is from 1 to 200 bar, preferably from 10 to 150 bar and more preferably from 15 to 100 bar.
The reaction temperature is between -20 °C and +120°C, preferably from 0 to 80°C and more preferably from 20 to 65°C.
The asymmetric hydrogenation is preferably effected with exclusion of oxygen.
The process according to the invention is optionally carried out in a solvent.
Suitable solvents are preferably organic solvents, for example alcohols, esters, amides, ethers, ketones, aromatic hydrocarbons and halogenated hydrocarbons. Particular preference is given to using protic solvents.
Examples of preferred solvents are ethyl acetate, methanol, i-propanol, acetone, tetrahydrofuran, dichloromethane, toluene or dibromoethane. If desired, it is also possible to use a mixture of one or more of the solvents listed above with water. The volume ratio of solvents to water is then preferably from 2:1 to 8:1, more preferably from 3:1 to 6:1. Preference is given to a mixture of one or more protic solvents with water, as a result of which a distinct increase in the enantiomeric purity can be achieved. The solvent used in the process according to the invention is more preferably a mixture of i-propanol and water.
The catalyst used in accordance with the invention is a catalyst system which comprises a transition metal from
the group of ruthenium, rhodium and iridium, and a combination of a chiral phosphorus ligand of the formula (II) and an achiral phosphine ligand of the formula (III).
The transition metal used is preferably ruthenium or rhodium, more preferably rhodium.
Chiral ligands of the formula (II) are known and are described, for example, in WO 02/04466 or WO 2004/035208.
In the formula (II), the alkyl, aryl, alkoxy,, aryloxy, aralkyl or alkaryl groups preferably have 1-20 carbon atoms and may optionally be substituted by one or more substituents from the group of hydroxyl, alkyl, alkoxy, phenyl, nitrile, carboxylic ester or halogen. R4 in the formula (II) is more preferably an optionally substituted, linear, branched or cyclic C1-CB-alkyl radical, an optionally substituted phenyl radical, an optionally substituted C1-CB-alkoxy radical, an optionally substituted phenyloxy radical or an NR5R6 group in which R5 and R6 are preferably each independently an optionally phenyl-substituted alkyl group having 1-6 carbon atoms, more preferably having 1-3 carbon atoms, or, together with the nitrogen atom, form a ring which may optionally also contain a heteroatom, for instance 0, N or S, for instance a morpholine ring, piperxdine ring, pyrrolidine ring, etc. More preferably, R5 and R6 with the nitrogen atom form a 5-Tnembered or 6-membered ring which may optionally also contain a heteroatom.
Cn is preferably a chiral, substituted C4 chain (chain with 4 optionally substituted carbon atoms) with predominantly one configuration, for example with an enantiomeric excess greater than 95% ee, preferably above 99% ee.
together with the two oxygen atoms and the phosphorus atom more preferably forms a 7-membered ring having 4 carbon atoms, in which case two carbon atoms in each case are part of an optionally substituted aryl group.
The aryl group is more preferably an optionally substituted phenyl or naphthyl group. The substituents are preferably attached in the o positions.
Examples of preferred chiral ligands of the formula (II) are compounds of the formula (Ila) and (lib)

where the naphthyl groups are optionally mono- or polysubstituted by halogen, for instance chlorine or bromine, alkyl, preferably C1-C6-alkyl, or alkoxy, preferably C1-Cs-alkoxy, aryl, preferably phenyl, aryloxy, preferably phenyloxy, R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-Ce-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, and R5 and R6 are each independently an optionally phenyl-substituted alkyl group having 1-6 carbon atoms, more preferably having 1-3 carbon atoms, or, together with the nitrogen atom, form a ring.
Further preferred chiral ligands of the formula (II) are compounds of the formula (lie) and (lid)

(Figure Removed)
where the phenyl groups are optionally mono- or polysubstituted by halogen, for instance chlorine or bromine; alkyl, preferably - alkyl, or alkoxy, preferably -alkoxy, aryl , preferably phenyl, aryloxy, preferably phenyl oxy, R4 is an optionally substituted -alkyl radical, an optionally substituted phenyl radical, an optionally phenyl -substituted - alkoxy radical or an optionally -alkyl- substituted phenyl oxy radical, and R5 and R6 are each independently an optionally phenyl -substituted alkyl group having 1-6 carbon atoms, more preferably having 1-3 carbon atoms, or, together with the nitrogen atom, form a ring.
Particularly preferred chiral ligands of the formula (II) are compounds of the formula (lie) and (Ilf)

in which R4 is an optionally substituted -alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-Ce-alkoxy radical or an optionally Cx-Ce-alkyl-substituted phenyloxy radical, R5 and R6 are each independently a Ca-C6-alkyl group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 a linear or branched
C1-C6-alkyi radical, an optionally substituted phenyl radical, an optionally phenyl -substituted
in which R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C^-alkoxy radical or an optionally C1-Cg-alkyl-substituted phenyioxy radical, R5 and R6 are each independently a d-Ce-alkyl group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 and R8 are each a linear or branched C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted d-C6-alkoxy radical, or an optionally C1-C6-alkyl-substituted phenyloxy radical.
The chiral ligands are used with an enantiomeric purity of at least 50% ee, preferably of at least 90% ee and more preferably of above 99% ee.
As a second ligand, the catalyst system used in accordance with the invention comprises an achiral phosphine ligand of the formula (III) P(R)3 in which R is an optionally substituted alkyl or aryl radical.
R is preferably a linear, branched, or cyclic alkyl radical having from 2 to 10 carbon atoms, more preferably having from 4 to 6 carbon atoms, or a phenyl radical optionally mono- or polysubstituted by halogen or C-.-Cr-alkyl.
Particularly preferred radicals are phenyl, o-tolyl, m-tolyl, p-tolyl, xylyl, m-chlorophenyl, p-chlorophenyl, o-methoxyphenyl, p-methoxyphenyl, m-methoxyphenyl, mesityl, cyclohexyl, n-butyl and t-butyl.
The ratio of chiral ligand of the formula (II) to achiral ligand of the formula (III) in the process according to the invention is from 10:1 to 1:5, preferably from 5:1 to 1:2, more preferably from 2.5:1 to 1.2:1.
The inventive catalyst system can be prepared analogously to WO 02/04466.
Preference is given to reacting the chiral ligand and
the achiral ligand with a catalyst precursor comprising
the transition metal.
Examples of suitable catalyst precursors are: (COD = 1, 5-cyclooctadiene, NBD = norbornadiene) [Rh(COD)2Cl]2, [Rh(COD)2]BF4, [Rh (NBD) 2] BF4, Ru(OAc)3,
Ru (methyialiyl) 2COD, [Ru (cymene) C12] 2/ etc.
The molar ratio of transition metal catalyst:chiral
ligand is from 1:0.5 to 1:5, preferably from 1:1 to
1:2.
The molar ratio of reactant:transition metal catalyst
is from 100:1 to 1 000 OOO-.l, preferably from 1000:1 to
10 000:1.
In the process according to the invention, for example, the substrate of the formula (I) , the ligands of the formulae (II) and (III) , and the precursor which comprises the transition metal are dissolved in the solvent in a suitable apparatus, for instance in an autoclave. Then, the apparatus is preferably purged with inert gas, for example with N2/ if the exclusion
of oxygen is desired. Then, rhe mixture is heated to the desired reaction temperature. However, preferably only -he substrate is dissolved first in the solvent, then the apparatus is purged, preferably with inert gas. After heating to the appropriate reaction temperature, a suspension of the ligands of the formula
(II) and (III) in degassed solvent and also the
precursor which comprises the transition metal are then
charged to the substrate solution.
Afterward, the hydrogen donor is added at the appropriate reaction temperature. Preference is given to injecting H2 to the desired pressure. After the reaction has ended and the reaction solution has optionally been cooled, the desired end product is isolated by customary methods depending on the state of matter.
It is also possible first to prepare the catalyst complex, for example by reacting the ligands (II) and
(III) with a precursor in a degassed solvent at room
temperature, by stirring the reaction mixture for a
certain time. Subsequently, the volatile compounds are
distilled off to obtain a solid catalyst complex which
is then added to the substrate solution.
The process according to the invention and in particular the use of the spec1fic catalyst system make it possible to hydrogenate the acrylic ac1d derivatives firstly in a substantially less expensive manner compared to the prior art and secondly in distinctly higher enantioselectively, as a result of which the end products have a distinctly higher optical purity.
The present invention further provides a catalyst system for asymmetric transition metal catalysis, which comprises a transition metal from group VIII, IX or X and a combination of a chiral phosphorus ligand of the formula (Ha) , (lib) , (lie) or (lid) and an achiral phosphine ligand of the formula (III)
in which R is an optionally substituted alkyl or aryl
The inventive catalyst system is suitable for asymmetric transition metal catalysis, in particular for transition metal-catalyzed asymmetric hydrogenation of unsarurated compounds.
The ratio of chiral ligand of the formulae (Ha) - (lid) to achiral ligand of the formula (III) may in this case be from 10:1 to 1:5.
The ratio is preferably from 5:1 to 1:2, more preferably from 2.5:1 to 1.2:1.
Suitable transition metals are elements of groups VIII, IX or X; preference is given to using ruthenium, rhodium or iridium.
The invention further provides for the use of the inventive catalyst system for the transition metal-catalyzed asymmetric hydrogenation of unsaturated compounds.
Example 1: Preparation of (R] -5-methoxy-3- (3-methorypropoxy)-a-(1-methylethyl)phenylpropanoic ac1d
In a 450 mi autoclave, 50 g (178.35 mmol) of E-2-[[4-meuhoxy-S-(3-methoxypropoxy)phenyl]methylene]-3-methylbutanoic ac1d, IOC mg (0.234 mmol) of ligand of the formula (lie) (%ee > 95%) (2,6-dimethyl-3,5-dioxa-4-phosphacyclohepta[2,1-a;3,4-a' ]dinaphthalen-4-yDpiperidine, 47.6 mg (0.1172 mmol) of Rh(COD)2BF4 and 30.8 mg (0.117 mraol) of triphenylphosphine were suspended in 160 ml of isopropanol (IPA) :H20 = 4:1. The autoclave was purged 5x with N2 and heated to 55°C. Afterward, it was purged 3x with H2 and subsequently pressurized to 80 bar of H2 without stirring. At 80 bar/55°C and 100 rptr. of the stirrer, the mixture was then hydrogenated overnight. After 18 h, the autoclave was cooled and the desired product was isolated. Yield: 50,35 g (96.6% of theory) Optical purity: 95.3% ee
Examples 2-8:
Analogously to Example 1, alpha-methyl c1nnamic ac1d was
hydrogenat ed.
The reaction parameters were selected as follows:
1 mmol of substrate, reaction temperature 30CC; 25 bar
of K2; 4 ml of solvent IPA:H20 = 4:1, reaction time
16 h; 0.01 mmol of Rh(COD) 2BF4, 0.02 mmol of chiral
ligand as in Example 1, 0.01 mmol of achiral ligand
P(R)3; see Table 1 for R.
were hydrogenated. The particular definition of the Rl
and R2 radicals is shown in Table 2.
The reaction parameters were selected as follows:
1 mmol of substrate, reaction temperature 30°C; 25 bar
of H2; 4 ml of solvent IPA:H20 = 4:1, reaction time
16 h; 0.01 mmol of Rh(COD)2BF4, 0.02 mmol of chiral
ligand as in Example 1 except that the ring in some
cases contains an oxygen atom (see Table 2), 0.01 mmol
of achiral ligand P(R)3; see Table 2 for R.Analogously to Examples 2-8, alpha-methylc1nnamic ac1d was hydrogenated. For comparison, hydrogenation was effected in each case once with use of an inventive ligand system consisting of the combination of chiral ligand and. achiral ligand PPh3 and once only with use of a chiral ligand (without achiral ligand).
The reaction parameters were selected as follows:
1 rnmol of substrate, reaction temperature 60°C; 25 bar
of H2; 4 ml of solvent IPA, reaction time 5 h;
0.01 mmol of Rh(COD)aBF4, 0.02 mmol of chiral ligand of
the following formula, and in some cases 0.01 mmol of(Table Removed)

What is claimed is:
I. A process for transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives of the formula (I)
II. (Formula Removed)
In which Rl is E or an optionally substituted C1-C20-alkyl, C5-C2o-aryi or C5-C20-heteroaryl radical, R2 is an optionally substituted C1-C20-alkyl, C5-C20)-aryl or C5-C20-heteroaryl radical, and R3 is H or :a C1-C6-alkyl radical, which comprises hydrogenating compounds of the formula (I) , optionally in a solvent, in the presence of one or more hydrogen donors, using a catalyst system which comprises a transition metal from the group of ruthenium, rhodium and iridium and a combination of a chiral phosphorus ligand of the formula (II)
(Formula Removed)
in which Cn, together with the two oxygen atoms and the phosphorus atom, forms an optionally substituted ring having from 2 to 6 carbon atoms and R4 is an optionally substituted alkyl, aryl, alkoxy or aryloxy radical or NR5R6 where R5 and R6 may each independently be H or an optionally substituted alkyl, aryl, aralkyl or alkaryl radical, or, together with the nitrogen atom, may
form a ring, and an achiral phosphine ligand of the formula (III)
in which R is an optionally substituted alkyl or aryl radical, to the corresponding compounds of the formula (IV)
(Figure Removed)
in which Rl, R2 and R3 are each as defined above.
2. The process as claimed in claim 1, wherein
suitable hydrogen donors act as solvents or the
solvents used are alcohols, esters, amides,
ethers, ketones, aromatic hydrocarbons and
halogenated hydrocarbons, optionally in
combination with water.
3. The process as claimed in claim 2, wherein the
solvents are used in combination with water, the
volume ratio of solvent to water being from 2:1 to
8:1.
4. The process as claimed in claim 3, wherein the
solvent used is a mixture of 2-propanol and water
in a volume ratio of from 3:1 to 6:1.
5. The process as claimed in one of claims 1 to 4,
wherein the hydrogen donor used is H2.
6. The process as claimed in one of claims 1 to 5,
wherein the reaction temperature is between -20DC
and +120°C.
7. The process as claimed in one of claims 1 to 6, wherein the chiral ligand is used with an enantiomeric purity of at least 90% ee.
8. The process as claimed in one of claims 1 to 7, wherein the transition metal used is ruthenium or rhodium.
9. The process as claimed, in one of claims 1 to 8, wherein chiral ligands of the formula (II) are used in which R4 is an optionally substituted, linear, branched of cycli C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally substituted C1-C6-alkoxy radical, an optionally substituted phenyloxy radical or an NR5R6 group where R5 and R6 are each independently an optionally phenyl-substituted alkyl group having 1-6 carbon atoms or, together with the nitrogen atom, form a ring which may optionally also contain a heteroatoin.
10. The process as claimed in one of claims 1 to 9, wherein chiral ligands of the formula (IIa), (Figure Removed)
ere the naphthyi and the phenyl groups may optionally be mono- or polysubstituted by halogen, alkyl, alkoxy, aryl or aryloxy, R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C6-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, and R5 and R6 are each independently a phenyl-substituted alkyl group having 1-6 carbon atoms or, together with the nitrogen atom, form a ring are used.
11. The process as claimed in one of claims 1-10, wherein chiral ligands of the formula (lie), (IIf), (IIg) or (IIh)
(Figure Removed)

in which R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C6-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, R5 and R6 are each independently a C1-C6-alky! group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 and R8 are each a linear or branched C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted d-Ce-alkoxy radical, or an optionally C1-C6-alkyl-substituted phenyloxy radical are used.
12. The process as claimed in one of claims 1-11,
wherein achiral ligands of the formula (III) are
used in which R is a linear, branched or cyclic
alkyl radical having from 2 to 10 carbon atoms or
a phenyl radical optionally mono- or
polysubstituted by halogen or C1-C6-alkyl.
13. The process as claimed in one of claims 1-12,
wherein the ratio of chiral ligand of the formula
(II) to achiral ligand of the formula (III) is from 10:1 to 1:5.
The process as claimed in one of claims 1-13, wherein the molar ratio of transition metal catalyst to chiral ligand of the formula (II) is from 1:0.5 to 1:5.
15. The process as claimed in one of claims 1-14,
wherein the transition metal is used in the form
of a catalyst precursor.
16. The process as claimed in one of claims 1-15,
wherein the substrate of the formula (I) , the
ligands of the formulae (II} and (III) , and the
precursor which comprises the transition metal are
first dissolved in the solvent in a suitable
apparatus, then the apparatus is optionally purged
with inert gas and then heated to the desired
reaction temperature, or only the substrate of the
formula (I) is first dissolved in the solvent,
then the apparatus is optionally purged with inert
gas, and only after heating to the appropriate
reaction temperature is a suspension of the
ligands of the formula (II) and (III) in degassed
solvent and also the precursor which comprises the
transition metal charged to the substrate
solution, and then, in both cases, the hydrogen
donor is added at the appropriate reaction
temperature.
17. A catalyst system for asymmetric transition metal
catalysis, which comprises a transition metal from
group VIII, IX or X and a combination of a chiral
phosphorus ligand of the formula (Ha) , (lib) ,
(IIe) or (IId)
(Figure Removed)
where the naphthyl and the phenyl groups may optionally be mono- or polysubstituted by halogen, alkyi, alkoxy, aryl or aryloxy, R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical, an optionally phenyl-substituted C1-C6-alkoxy radical or an optionally C1-C6-alkyl-substituted phenyloxy radical, and R5 and R6 are each independently a phenyl-substituted alkyl group having 1-6 carbon atoms or, together with the nitrogen atom, form a ring,
and an achiral phosphine ligand of the formula (III) P(R)3
in which R is an optionally substituted alkyl or aryl radical.
The catalyst system as claimed in claim 17, wherein the transition metal used is ruthenium, rhodium or iridium.
19. The catalyst system as claimed in claim 17 or 18, wherein the chiral ligand used is a ligand of the formula (He) , (IIf) , (Ilg) or (IIh)
(Figure Removed)
in which R4 is an optionally substituted C1-C6-alkyl radical, an optionally substituted phenyl radical or an optionally phenyl-substituted C1-C6-alkoxy radical, R5 and R6 are each independently a C1-C6-alkyl group or, together with the nitrogen atom, form a 5-membered or 6-membered ring which may optionally also contain an oxygen or sulfur atom, and R7 and RB are each a linear or branched C1-C6-alkyl radical.
20. The catalyst system as claimed in one of claims 17
to 19, wherein the molar ratio of chiral ligand to
achiral ligand is from 2.5:1 to 1.2:1.
21. The use of a catalyst system as claimed in one of
claims 17 to 20 in transition metal-catalyzed
asymmetric hydrogenation of unsaturated compounds.
22. The use as claimed in claim 21, wherein the unsaturated compounds are acrylic acid derivatives of the formula (I)
(Formula Removed)
in which R1 is H - optionally substituted alkyl, C5-C20{aryl or C5-C20-heteroar%'l .radical, R2 is an 4ptionally substituted C2-C20-aikyl, C5-C20-aryl or -heteroaryl radical, and R3 is H or a C2-C6-alKyl radical.

Documents:

3911-delnp-2007-abstract.pdf

3911-delnp-2007-Claims-(20-11-2013).pdf

3911-delnp-2007-claims.pdf

3911-delnp-2007-Correspondence Others-(20-11-2013).pdf

3911-delnp-2007-Correspondence Others-(20-12-2013).pdf

3911-delnp-2007-Correspondence-Others-(22-05-2013).pdf

3911-delnp-2007-correspondence-others.pdf

3911-delnp-2007-description (complete).pdf

3911-delnp-2007-form-1.pdf

3911-delnp-2007-form-2.pdf

3911-delnp-2007-Form-3-(20-11-2013).pdf

3911-delnp-2007-form-3.pdf

3911-delnp-2007-form-5.pdf

3911-delnp-2007-GPA-(20-11-2013).pdf

3911-delnp-2007-gpa.pdf

3911-delnp-2007-pct-210.pdf

3911-delnp-2007-pct-304.pdf

3911-delnp-2007-Petition-137-(20-11-2013).pdf

« Previous Patent

Next Patent »

Patent Number

258198

Indian Patent Application Number

3911/DELNP/2007

PG Journal Number

51/2013

Publication Date

20-Dec-2013

Grant Date

16-Dec-2013

Date of Filing

24-May-2007

Name of Patentee

DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG

Applicant Address

ST-PETER-STRASSE 25, A-4021 LINZ, AUSTRIA

Inventors:

#	Inventor's Name	Inventor's Address
1	BOOGERS, JEROEN	MOSALUNET 12D, NL-6221 JM MAASTRICHT, THE NETHERLANDS
2	FELFER, ULFRIED	HOFMANNSTRASSE 2, A-4020 LINZ, AUSTRIA
3	KOTTHAUS, MARTINA	HANRIEDERSTRASSE 22, A-4020 LINZ, AUSTRIA
4	DE VRIES, ANDREAS HENDRIKUS MARIA	BURGEMEESTER CEULENSTRAAT 75, NL-6212 CT MAASTRICHT, THE NETHERLANDS
5	DE VRIES, JOHANNES GERARDUS	BORNEDAAL 33, NL-6228 GZ MAASTRICHT, THE NETHERLANDS
6	LEFORT, LAURENT	KLEINE LOOIEERSTRAAT 2A, NL-6211 JL MAASTRICHT, THE NETHERLANDS
7	STEINBAUER, GERHARD	LORCH 21, A-4470 ENNS, AUSTRIA

PCT International Classification Number

B01J 31/24

PCT International Application Number

PCT/EP2005/012990

PCT International Filing date

2005-12-05

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	A 2174/2004	2004-12-27	Austria